INCY
NASDAQIncyte Corp.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Price$104.42+0.31 (+0.30%)
01:30 PM07:45 PM
News · 26 weeks1030%
2025-12-282026-06-21
Mix6290d
- Insider25(40%)
- Other20(32%)
- SEC Filings10(16%)
- Earnings3(5%)
- Leadership2(3%)
- Analyst2(3%)
Latest news
25 items- ANALYSTIncyte upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Incyte from Underperform to Market Perform and set a new price target of $94.00
- SECIncyte Corp. filed SEC Form 8-K: Other Events8-K - INCYTE CORP (0000879169) (Filer)
- PRIncyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). "This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. "We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer." DLBCL is the most common subtype of non-Hodgkin lymphoma and is
- PRMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-
- PRIncyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential ThrombocythemiaIn myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib In essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks) Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential fo
- PRResults from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global re
- INSIDERDirector Baker Bros. Advisors Lp was granted 3,284 shares (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Harrigan Edmund was granted 1,642 shares, increasing direct ownership by 8% to 22,764 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Clancy Paul J was granted 1,642 shares, increasing direct ownership by 7% to 25,383 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Fouse Jacqualyn A was granted 1,642 shares, increasing direct ownership by 8% to 20,968 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Bienaime Jean Jacques was granted 1,642 shares, increasing direct ownership by 7% to 24,424 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector High Katherine A was granted 1,642 shares, increasing direct ownership by 12% to 14,983 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Brawley Otis W was granted 1,642 shares, increasing direct ownership by 15% to 12,894 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- SECIncyte Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - INCYTE CORP (0000879169) (Filer)
- INSIDERPrincipal Accounting Officer Tray Thomas sold $263,900 worth of shares (2,639 units at $100.00) and exercised 2,639 shares at a strike of $83.83 (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- SECIncyte Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - INCYTE CORP (0000879169) (Filer)
- PRIncyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones - Incyte will host an analyst and investor call on Monday, June 8, 2026, at 8:00 a.m. ET Incyte (NASDAQ:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales
- PRMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva ("FOP") will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604863826/en/
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 25,469 shares, decreasing direct ownership by 10% to 240,848 units (SEC Form 4) to cover taxes4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCLThe Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes The frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide adde
- INSIDERPrincipal Accounting Officer Tray Thomas sold $199,665 worth of shares (2,051 units at $97.35), decreasing direct ownership by 9% to 21,132 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Bienaime Jean Jacques exercised 15,000 shares at a strike of $84.53 and covered exercise/tax liability with 13,059 shares, increasing direct ownership by 9% to 22,782 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- SECSEC Form DEFA14A filed by Incyte Corp.DEFA14A - INCYTE CORP (0000879169) (Filer)
- PRIncyte to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Invest
- ANALYSTBernstein initiated coverage on Incyte with a new price targetBernstein initiated coverage of Incyte with a rating of Mkt Perform and set a new price target of $99.00
INCY FAQ
6 questionsWhat does Incyte Corp. do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial...Where does INCY stock trade?
Incyte Corp. (INCY) is listed on NASDAQ.What sector and industry is INCY in?
Incyte Corp. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about INCY?
Incyte Corp. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform on 2026-06-22.What companies are similar to INCY?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc), SYNH (Syneos Health Inc.). Compare INCY side-by-side with any of them on Quantisnow.How can I track INCY on Quantisnow?
Quantisnow aggregates Incyte Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCY to receive live email and push alerts on every new disclosure.